TG4050

AXP000183.1 · Cancer vaccine

Platform
MVA (individualised neoantigens)
Originator
Transgene
Sponsor
Transgene

Names

NameTypeSource
TG4050preferred name, codecurator, ncit

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
MVA
Replication
non replicating
Modifications
patient-specific neoantigen cassette inserted into MVA
Transgenes
individualised tumour neoantigens
Source
evidence

Cross-references

NCI Thesaurus
C171392

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04183166A Clinical Trial Evaluating TG4050 in Head and Neck CancerActive not recruitingPhase 1/22019-12-122027-12-3080Squamous Cell Carcinoma of Head and Neck
NCT03839524A Trial Evaluating TG4050 in Ovarian Carcinoma.CompletedPhase 12019-12-092024-10-0864Fallopian Tube Cancer; Ovarian Carcinoma; Peritoneal Carcinoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42744798A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial.Nature communications2026cited by trial NCT04183166

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41830840Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation.Translational oncology2026name in abstract: TG4050

Notes

Individualised MVA vaccine encoding patient-specific neoantigens selected with NEC's AI platform; phase 1/2 trials in head and neck and ovarian cancer (US, UK, France). Route not recorded here.

How to cite

TG4050 (AXP000183.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000183.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.